Tirzepatide, development code LY3298176, is a synthetic 39-residue lipidated peptide with agonist activity at two receptors: GIP and GLP-1. It is the active ingredient in FDA-approved medicines, and its published record runs from receptor pharmacology and mouse work to large phase 3 trial programs. Those approvals cover specific drug products made, labeled and prescribed under […]
Retatrutide, development code LY3437943, is a synthetic 39-residue lipidated peptide with agonist activity at three receptors: GIP, GLP-1 and glucagon. Its published record runs from receptor pharmacology and rodent work to phase 1, phase 2 and phase 3 clinical trials, all sponsored by its developer. That record describes an investigational medicine studied under clinical protocols. […]
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence GEPPPGKPADDAGLV. Its sequence is described as a partial fragment of a larger body protection compound isolated from human gastric juice. Its published literature is almost entirely preclinical: rodent injury models, cultured cells and a small number of uncontrolled human reports. That […]